Otsuka to acquire renal denervation firm ReCor Medical

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension.

Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients with high blood pressure in the U.S. and E.U. In May 2016 the duo inked a deal that gave Otsuka exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea and elsewhere in Asia.

Get the full story on our sister site MassDevice.

From the Hospital Bed to the Finish Line Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist. You can hear her story and more when you register for DeviceTalks Boston, October 8-10. REGISTER NOW Use code FINISHLINE to save an additional 10%.